

Olivier SORDET

Research scientist (CR INSERM), Ph.D.
Co-director of the team “Cancer cell signalling and therapeutics” at CRCT

Date of birth: September 5th 1971

French nationality

ResearcherID: <https://publons.com/researcher/2480024/olivier-sordet/>

ORCID: <https://orcid.org/0000-0001-6027-4925>

Cancer Research Center of Toulouse (CRCT)
INSERM UMR1037
2 avenue Hubert Curien
31037 Toulouse Cedex
Phone: (33) 5 82 74 16 11 / Email: olivier.sordet@inserm.fr

Degrees and diplomas

- 2010: HDR (Habilitation à Diriger des Recherches), Toulouse, France
- 2001: Ph.D. in Biochemistry, Cellular and Molecular Biology, Dijon, France
- 1997: M.Sc. in Biochemistry, Cellular and Molecular Biology, Dijon, France

Additional training in France and elsewhere

- December 2008 to present: Research scientist – CRCT, INSERM U1037, Toulouse (France)
- 2002-2008: Post-doctoral Research Fellow, National Institutes of Health (NIH), Bethesda (USA)
- 1997-2001: Ph.D. candidate, INSERM U517, Dijon (France)

Other activities

- Co-director of the team “Cancer cell signalling and therapeutics” at CRCT since January 2021
- Supervision of Master students (10), Ph.D. students (6) and Post-docs (3)
- Reviewing activity for journals (17 in the last 5 years for Cell Rep, Nat Commun, Nucleic Acids Res, PLoS Genet, ...), and national and international grants (9 in the last 5 years for LNCC, NWO-ECHO grants, KWF, Worldwide Cancer Research...)
- Jury member for the Master 2 oncology of Toulouse (2017-2018), and for jury thesis (4)

Grants and awards

- Grants from charities (ARC, LNCC, Fondation de France, GSO) and companies (AstraZeneca)
- Fare awarded by the National Institutes of Health (NIH), 2004

52 Publications in peer-reviewed journals, including Cell Rep, EMBO Rep, PNAS, Cancer Res (4), Nucleic Acids Res (1), Mol Cell Biol (2), J Biol Chem (4), Blood (5), and Oncogene (3).
h-index: 32; number of times cited: 3,399.

10 major publications

- 1: Cristini A, Ricci G, Britton S, Salimbeni S, Huang SN, Marinello J, Calsou P, Pommier Y, Favre G, Capranico G, Gromak N*, Sordet O*. Dual Processing of R-Loops and Topoisomerase I Induces Transcription-Dependent DNA Double-Strand Breaks. **Cell Rep**. 2019 Sep 17;28(12):3167-3181.e6. doi: 10.1016/j.celrep.2019.08.041.*Co-corresponding authors. PMID: PMID: [31533039](https://pubmed.ncbi.nlm.nih.gov/31533039/)
- 2: Mouly L, Mamouni K, Gence R, Cristini A, Cherier J, Castinel A, Legrand M, Favre G, Sordet O*, Monferran S*. PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin. **Cell Death Dis**. 2018 Sep 12;9(9):931. doi: 10.1038/s41419-018-0981-3.*Co-last and co-corresponding authors. PMID: [30209297](https://pubmed.ncbi.nlm.nih.gov/30209297/)
- 3: Cristini A, Park JH, Capranico G, Legube G, Favre G, Sordet O*. DNA-PK triggers histone ubiquitination and signaling in response to DNA double-strand breaks produced during the repair of transcription-blocking topoisomerase I lesions. **Nucleic Acids Res**. 2016 Feb 18;44(3):1161-78. doi: 10.1093/nar/gkv1196.*Corresponding author. PMID: [26578593](https://pubmed.ncbi.nlm.nih.gov/26578593/)

- 4: Mamouni K, Cristini A, Guirouilh-Barbat J, Monferran S, Lemarié A, Faye JC, Lopez BS, Favre G*, Sordet O*. RhoB promotes γ H2AX dephosphorylation and DNA double-strand break repair. **Mol Cell Biol**. 2014 Aug;34(16):3144-55. doi: 10.1128/MCB.01525-13. *Co-last and co-corresponding authors. PMID: [24912678](#)
- 5: Sordet O, Redon CE, Guirouilh-Barbat J, Smith S, Solier S, Douarre C, Conti C, Nakamura AJ, Das BB, Nicolas E, Kohn KW, Bonner WM, Pommier Y. Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. **EMBO Rep**. 2009 Aug;10(8):887-93. doi: 10.1038/embor.2009.97. PMID: [19557000](#)
- 6: Sordet O, Larochelle S, Nicolas E, Stevens EV, Zhang C, Shokat KM, Fisher RP, Pommier Y. Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I. **J Mol Biol**. 2008 Sep 5;381(3):540-9. doi: 10.1016/j.jmb.2008.06.028. PMID: [18588899](#)
- 7: Sordet O, Goldman A, Redon C, Solier S, Rao VA, Pommier Y. Topoisomerase I requirement for death receptor-induced apoptotic nuclear fission. **J Biol Chem**. 2008 Aug 22;283(34):23200-8. doi: 10.1074/jbc.M801146200. PMID: [18556653](#)
- 8: Sordet O, Liao Z, Liu H, Antony S, Stevens EV, Kohlhagen G, Fu H, Pommier Y. Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis. **J Biol Chem**. 2004 Aug 6;279(32):33968-75. PMID: [15178684](#)
- 9: Sordet O*, Rébé C*, Plenchette S, Zermati Y, Hermine O, Vainchenker W, Garrido C, Solary E, Dubrez-Daloz L. Specific involvement of caspases in the differentiation of monocytes into macrophages. **Blood**. 2002 Dec 15;100(13):4446-53. *Co-first authors. PMID: [12393560](#)
- 10: Sordet O, Rébé C, Leroy I, Bruy JM, Garrido C, Miguet C, Lizard G, Plenchette S, Corcos L, Solary E. Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. **Blood**. 2001 Jun 15;97(12):3931-40. PMID: [11389037](#)